What is MS Phase 2B Study MIS416?

Category: Others


MIS416 is a new experimental medication in clinical trial studies for secondary progressive multiple sclerosis. MIS416 is microparticle derived from bacteria, combined with two immune-modifying molecules. It acts to stimulate a specific range of responses in the immune system.


Based on patients currently using MS Phase 2B Study MIS416

Dosage Patients
50 mcg weekly 1


Currently using MS Phase 2B Study MIS416

Duration Patients
2 - 5 years 1
Last updated:
There are no evaluations for MS Phase 2B Study MIS416.